Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation. This report summarizes the safety and efficacy of lomefloxacin in the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, acute exacerbations of chronic bronchitis, and for prophylaxis during urinary tract surgery. The clinical data presented are an overview of all clinical studies conducted in the United States to date. The results have been derived from multiple studies in which patients received lomefloxacin or a comparative agent in either blinded or open-label studies. During the course of the clinical program in the United States, lomefloxacin has been compared with oral norfloxacin, ciprofloxacin, and cefaclor, as well as parenteral cefotaxime. In all instances, the once-daily oral administration of lomefloxacin was either equally effective or statistically significantly superior in clinical and/or bacteriologic efficacy to these comparative agents. In addition, the comparators were administered either two or three times per day, except in the surgical prophylaxis studies, in which single doses of each antibiotic were administered preoperatively. These results attest to the value of the convenience and simplicity of the oral dosing regimen for lomefloxacin. During the course of the clinical program, lomefloxacin was well tolerated, with most adverse events of mild to moderate severity. In general, the incidence of adverse events for patients and subjects receiving lomefloxacin was comparable to that observed in patients treated with comparator drugs. The most common adverse events were related to the gastrointestinal tract (nausea and diarrhea), the skin and appendages (photosensitivity), and the central nervous system (dizziness and headache). A sub-analysis of adverse events in the respiratory studies demonstrated that concomitant administration of lomefloxacin and theophylline does not increase the incidence of adverse events when compared to lomefloxacin alone. An additional sub-analysis also showed that the incidence of adverse events in elderly patients was similar to that in younger patients. The results of the U.S. clinical program indicate that lomefloxacin administered orally once daily is effective and well tolerated in a variety of infections of bacterial origin.
 ...
PMID:The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. 131 63

Lomefloxacin, an orally active difluorinated quinolone, is active against a wide variety of clinically relevant Gram-negative and Gram-positive organisms. A totoal of 3387 evaluable patients received (both complicated and uncomplicated), acute exacerbations of chronic bronchitis, acute bacterial diarrhea, skin and skin structure infections, or for prophylaxis during urinary tract surgery or instrumentation. In these studies lomefloxacin was compared with oral norfloxacin, ciprofloxacin, trimethoprim/sulfamethoxazole, amoxicillin and cefaclor, and the parenteral agents cefotaxime and cefuroxime. Once-daily oral administration of lomefloxacin was either equally effective or statistically significantly superior in clinical and/or bacteriologic efficacy to comparative agents that were administered two or three times per day (except for prophylaxis studies, in which single doses of each antibiotic were administered preoperatively). The safely of lomefloxacin was assessed in 3246 patients and subjects. Most adverse events were mild to moderate in severity. In general, the incidence of adverse events for patients and subjects receiving lomefloxacin was comparable to that observed in patients treated with comparative drugs. The incidence of adverse events in elderly patients was similar to that observed in younger patients. Concurrent administratopm of the ophylline did not increase the incidence of adverse events. The most common adverse events were related tothe gastrointestinal tract (nausea), the skin and appendages (photosensitivity) and the central nervous system (dizziness). Lomefloxacin, administered orally once daily, is effective and well tolerated in patients with a variety of infections of bacterial origin.
 ...
PMID:A worldwide clinical overview of lomefloxacin, a once-daily fluoroquinolone. 1861 22